| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Sephience | — | — | — | — | — | $19.56M | $91.59M | $124.55M |
| Translarna | $70.35M | $72.28M | — | $86.15M | $59.47M | $50.67M | -$294.92M | $58.98M |
| Emflaza | $47.3M | $51.94M | $50.5M | $47.79M | $36.35M | $35.16M | $27.06M | $21.48M |
| Other Products | — | — | — | — | $10.62M | $9.83M | $5.99M | $10.97M |
| Upstaza And Kebilidi | — | — | — | — | — | — | — | $9.59M |
| Collaboration And License Revenue | $0 | — | — | $989.8M | — | — | — | — |
| Total | $186.7M | $196.79M | $213.17M | $1.18B | $178.88M | $211.01M | $164.68M | $272.55M |
Translarna1 is derived from annual filings.